Incidence and risk of severe infections associated with aflibercept in cancer patients: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Incidence and risk of severe infections associated with aflibercept in cancer patients: a systematic review and meta-analysis

Published:2015-10-30 Issue:1 Volume:81 Page:33-40
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Zhang Xi¹,Ran Yuge¹,Shao Yongjie²,Wang Kunjie³,Zhu Yuanxue³

Affiliation:

1. Department of Radiation Oncology; Affiliated Hospital of Hebei University; Baoding 071000

2. Department of Intervention; Affiliated Hospital of Hebei University; Baoding 071000

3. Department of Medical Oncology; Affiliated Hospital of Hebei University; Baoding 071000 China

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.12758/fullpdf

Reference28 articles.

1. Role of angiogenesis in tumor growth and metastasis;Folkman;Semin Oncol,2002

2. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis;Hicklin;J Clin Oncol,2005

3. VEGF-Trap: a VEGF blocker with potent antitumor effects;Holash;Proc Natl Acad Sci U S A,2002

4. FDA approves aflibercept (zaltrap) for metastatic colorectal cancer;Oncology (Williston Park),2012

5. North Central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane;Sideras;Clin Breast Cancer,2012

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of antiangiogenic adverse events in metastatic colorectal cancer patients receiving aflibercept in combination with chemotherapy: A meta-analysis;Medicine;2023-09-01

2. Efficacy, safety, and cost-effectiveness analysis of aflibercept in metastatic colorectal cancer: A rapid health technology assessment;Frontiers in Pharmacology;2022-08-30

3. Risk and Incidence of Infection with Bevacizumab in Non-Small-Cell Lung Cancer Patients: A Meta-Analysis;Oncology Research and Treatment;2022

4. Cell-Surface Receptors: EGFR- and VEGFR-Targeted Agents;Infectious Complications in Biologic and Targeted Therapies;2022

5. Cardiovascular Adverse Events With Intravitreal Anti–Vascular Endothelial Growth Factor Drugs;JAMA Ophthalmology;2021-06-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3